We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
- Authors
Regan, Meredith M; Leyland-Jones, Brian; Bouzyk, Mark; Pagani, Olivia; Tang, Weining; Kammler, Roswitha; Dell'orto, Patrizia; Biasi, Maria Olivia; Thürlimann, Beat; Lyng, Maria B; Ditzel, Henrik J; Neven, Patrick; Debled, Marc; Maibach, Rudolf; Price, Karen N; Gelber, Richard D; Coates, Alan S; Goldhirsch, Aron; Rae, James M; Viale, Giuseppe; Breast International Group (BIG) 1-98 Collaborative Group
- Abstract
Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy. In this study, we investigated the clinical relevance of CYP2D6 polymorphisms.
- Publication
Journal of the National Cancer Institute, 2012, Vol 104, Issue 6, p441
- ISSN
1460-2105
- Publication type
Journal Article
- DOI
10.1093/jnci/djs125